Evidence map›Paper›PMID 38444587›Full record

ReviewFrontiers in endocrinology2024

Animal models for type 1 and type 2 diabetes: advantages and limitations.

Raj Singh, Mazaher Gholipourmalekabadi, Sasha H Shafikhani

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 2 pooled it
60.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Biology · 2026
    Review
  9. Article
  10. Article
  11. Exosomes in precision dermatology: From biomarkers to targeted therapeutics in personalized care.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Review
  12. Article
  13. Phytochemical and Preliminary Biological Evaluation ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Raj SinghDepartment of Medicine, Division of Hematology, Oncology, & Cell Therapy, Rush University Medical Center, Chicago, IL, United States.
Mazaher GholipourmalekabadiCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
Sasha H ShafikhaniDepartment of Medicine, Division of Hematology, Oncology, & Cell Therapy, Rush University Medical Center, Chicago, IL, United States.
Rush University Medical Center · USIran University of Medical Sciences · IR

Funding

Role of immune system in prophylaxis antibiotic's surgical site infection controlR01AI150668 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SHAFIKHANI, SASHA H · 2020 to 2024
$2.0M
Assessment of CCL3 Therapy in Diabetic Wound CareR01DK135557 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SASHA H SHAFIKHANI · 2024 to 2026
$1.9M
Factors Leading to Enhanced Pseudomonas Aeruginosa Infection in Diabetic WoundsR01DK107713 · NIDDK · RUSH UNIVERSITY MEDICAL CENTER · PI SHAFIKHANI, SASHA H · 2016 to 2020
$1.7M
NIAID NIH HHS R01 AI150668NIDDK NIH HHS R01 DK107713NIDDK NIH HHS R01 DK135557
6 · The paper itself

Abstract

Diabetes mellitus, commonly referred to as diabetes, is a group of metabolic disorders characterized by chronic elevation in blood glucose levels, resulting from inadequate insulin production, defective cellular response to extracellular insulin, and/or impaired glucose metabolism. The two main types that account for most diabetics are type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), each with their own pathophysiological features. T1D is an autoimmune condition where the body's immune system attacks and destroys the insulin-producing beta cells in the pancreas. This leads to lack of insulin, a vital hormone for regulating blood sugar levels and cellular glucose uptake. As a result, those with T1D depend on lifelong insulin therapy to control their blood glucose level. In contrast, T2DM is characterized by insulin resistance, where the body's cells do not respond effectively to insulin, coupled with a relative insulin deficiency. This form of diabetes is often associated with obesity, sedentary lifestyle, and/or genetic factors, and it is managed with lifestyle changes and oral medications. Animal models play a crucial role in diabetes research. However, given the distinct differences between T1DM and T2DM, it is imperative for researchers to employ specific animal models tailored to each condition for a better understanding of the impaired mechanisms underlying each condition, and for assessing the efficacy of new therapeutics. In this review, we discuss the distinct animal models used in type 1 and type 2 diabetes mellitus research and discuss their strengths and limitations.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2AnimalsBlood GlucoseInsulinModels, AnimalBlood GlucoseInsulinanimal modelsanimal models for type 1 diabetes (T1D)animal models for type 2 diabetes (T2D)diabetesdiabetes mellitustype 1 diabetes (T1D)type 2 diabetes (T2D)

Identifiers

PMID38444587
PMCPMC10912558
OpenAlexW4391968006

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.